Johnson & Johnson JNJ

$273.20 -2.00 (-0.73%)

Valuation

Market cap
657,677,120,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
P/E (trailing)
25.84
P/E (forward)
24.76
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
8,969,400
Avg volume
6,971,910
Day's range
$273.13 – $282.02
Shares out
2,407,310,000
Stochastic %K
68%
Beta
0.21
Analysts
Moderate Buy
Price target
$281.88

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

viggizags Nov 1, 2:38 PM
$SPY real post: We probably got a bounce coming, we do have problems though. I really like neutrality while volatility is fairly elevated capture that by selling options on both sides. Consensus does seem to me like this move was all. I happen to think more sideways till end of the year range is still 7900-7500 with possible extention to the downside at 7250. That left tail is still fatter over time vs the right tail. I dont think its worth the risk more than just a trade but there are ton and tons of long side opportunities out there that most will miss and just chase tech stocks to underperform. Like best example is Woody Johnson coin $JNJ (no personal position)
0 replies
thatsolardude365 Nov 1, 6:13 AM
$JNJ: per the June 1, 2026 JPML report, 68,029 talc cases are pending in MDL 2738, out of 70,712 filed in total. No global settlement and no claim form, active litigation only. Open Class Actions.
0 replies
Stocktradesmoon Nov 1, 12:29 AM
$ABCL $MRNA $SLS $LLY $JNJ 🚨UPDATE: ABcellera 🔥 🔥!!! ABCL Q3 EARNINGS AND CLINICAL CATALYSTS $ABCL has announced its participation schedule for the November investor conference. I see this announcement as more than just a notice for an institutional investor event—it’s connected to the next clinical phase of ABCL635. In particular, we need to watch whether the 12-week data we’re ve all been waiting for will be unveiled during the November 9 earnings release, or if it will lead to a separate announcement afterward. 1. 👀Upcoming Key Schedule October 22 Poster presentation on ABCL635 Phase 1/2 clinical trial at the TMS 2026 Conference November 9 Q3 2026 Earnings Release and Conference Call 7:00 AM Korea Time on November 10 November 11 Stifel Healthcare Conference November 16 Jefferies Global Healthcare Conference Q4 2026 ABCL575 Phase 1 clinical results presentation scheduled By end of 2026 Expect 12-week data for ABCL635 and updates on subsequent clinical information
0 replies
Outcomes Oct 31, 4:47 PM
$MRNA $PFE $JNJ $IBRX ….eureka! mRNA BAD. https://x.com/mercuryconsul/status/2116294593428017543?s=46
0 replies
viggizags Oct 31, 1:51 PM
$SPY i dont think anyone realizes that Woody Johnson coin has outperformed so much that its contributed to more than 2% of the gains in the index $JNJ you dont have to simply chase tech and only tech just for one example. Woody Johnson coin ripping. Boring is exciting
0 replies
thatsolardude365 Oct 30, 9:44 PM
$JNJ: no talc claim portal exists. With MDL 2738 still in mediation and no global deal, ovarian cancer cases move only as individual suits after attorney review. J&J denies the allegations. Open Class Actions.
0 replies
KingTrades09 Oct 30, 9:37 PM
$IBM still holding $JNJ sold today at 280 $WMT sold half backed each one with a chart
0 replies
DidYouReadThis Oct 30, 7:07 PM
$NVS $BAYRY $RHHBY $JNJ Any other #FDA approvals that you would say were big ones for 2026 to add to the #watchlist for 2027?
0 replies